[The treatment with biosynthetic growth hormone (GH) of familial short stature].
The effect of growth hormone (GH) treatment in non-GH deficient subjects has been amply studied over the past few years. Although the results of these studies are encouraging, there are still no definitive data since the findings are not comparable due to the different characteristics of the populations examined. In the present study the authors examined the following parameters: stature, height SDS, growth rate, bone age and final height prediction according to Tanner, pubertal stage, before and after treatment with biosynthetic GH at a dose of 1.4 IU/kg of bodyweight for 12 months. The population treated consisted of 10 subjects (5 males and 5 females) aged between 7.3 and 9.5 years old, all prepubertal, with "familial short stature", selected according to the following criteria: stature below the 3rd centile, normal growth rate, normal GH response to stimuli using clonidine and insulin, correlation with parental stature between 25th and 75th centile, bone age correlated to chronological age, absence of other pathologies. After 12 months height SDS moved from -2.75 +/- 0.26 to -2.23 +/- 0.25 (p < 0.5); the growth rate changed from 5.75 +/- 0.63 to 6.66 +/- 0.56 (p < 0.05). No abnormal acceleration of bone age as observed: it moved from 8.2 +/- 0.62 to 9.5 +/- 0.72; all subjects continued to be prepubertal. The expected final stature changed from 154 +/- 2.38 to 159 +/- 0.7 (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Farello
G
G
Facoltà di Medicina e Chirurgia, Università degli Studi di L'Aquila.
De Simone
M
M
Gentile
T
T
De Matteis
F
F
D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects; D002648:Child; D004341:Drug Evaluation; D004393:Dwarfism, Pituitary / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D013997:Time Factors
D013006:Growth Hormone
Trattamento con ormone della crescita biosintetico (GH) della bassa statura familiare.